Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 77, Issue 11, Pages 1397-1407
Publisher
Elsevier BV
Online
2021-03-18
DOI
10.1016/j.jacc.2021.01.044
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Covariate adjusted reanalysis of the I-Preserve trial
- (2020) João Pedro Ferreira et al. Clinical Research in Cardiology
- Adjusting for adherence in randomized trials when adherence is measured as a continuous variable: An application to the Lipid Research Clinics Coronary Primary Prevention Trial
- (2020) Kerollos Nashat Wanis et al. Clinical Trials
- Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
- (2020) Kieran F Docherty et al. EUROPEAN HEART JOURNAL
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF
- (2017) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril
- (2017) Akshay S. Desai et al. JAMA Cardiology
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
- (2016) Yshai Yavin et al. Diabetes Therapy
- Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
- (2016) Yshai Yavin et al. Diabetes Therapy
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started